Clinical Trial Update: A Study to Evaluate V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age (V181-005/MOBILIZE-1) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial to evaluate the V181 dengue vaccine in healthy participants aged 2 to 17, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue Fever

Drugs mentioned

• V181 Dengue Vaccine

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Healthy | Phase 3 | Status: RECRUITING